Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What hypofractionated protocols should be tested for prostate cancer?

Jack F Fowler1, Mark A Ritter, Rick J Chappell

  • 1Department of Human Oncology, University of Wisconsin-Madison, Madison, WI 53792, USA. jffowler@mail.humonc.wisc.edu

International Journal of Radiation Oncology, Biology, Physics
|June 28, 2003
PubMed
Summary

Hypofractionated radiotherapy for prostate cancer shows potential for improved tumor control and reduced side effects. This approach offers therapeutic gain with minimal risk when using appropriate fraction numbers and treatment durations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Intraocular Pressure-Lowering Drops on the Tear Film Assessed by a Novel High-Resolution Tear Film Imager.

Diagnostics (Basel, Switzerland)·2026
Same author

Estimating temporal treatment-effect patterns of radiotherapy and chemotherapy in lower-grade gliomas using causal machine learning.

Scientific reports·2026
Same author

Further insights on the antimicrobial effectiveness of far-UVC light.

Photochemistry and photobiology·2026
Same author

Depth of DNA photodamage in human corneas exposed to 222 nm or 254 nm UV.

Photochemistry and photobiology·2026
Same author

Ultraviolet radiation dosimetry using radiochromic film for extended dose range applications and estimating eye exposure.

Radiation protection dosimetry·2026
Same author

Rainer Kurt Sachs 1932-2024.

Radiation research·2025

Area of Science:

  • Radiation Oncology
  • Medical Physics
  • Oncology

Background:

  • Prostate tumors exhibit a significantly lower alpha/beta ratio (around 1.5 Gy) compared to other cancers (typically 10 Gy).
  • This low alpha/beta ratio is comparable to or lower than surrounding rectal mucosa (nominally 3 Gy, likely 4-5 Gy).
  • The differential radiosensitivity between prostate tumors and rectal tissue presents an opportunity for therapeutic gain in radiotherapy.

Purpose of the Study:

  • To analyze potential high-gain, low-risk hypofractionated radiotherapy protocols for prostate cancer.
  • To evaluate the therapeutic potential arising from the low alpha/beta ratio of prostate tumors relative to rectal tissues.
  • To investigate the feasibility of hypofractionation schedules that optimize tumor control while minimizing normal tissue complications.

Related Experiment Videos

Main Methods:

  • Utilized standard linear-quadratic (LQ) modeling to design hypofractionated protocols.
  • Adjusted dose per fraction and total dose to maintain constant late complication levels in rectal tissues.
  • Investigated the impact of these adjusted schedules on tumor control, based on theoretical modeling and current alpha/beta parameter estimates.

Main Results:

  • Hypofractionated schedules with approximately ten large fractions can increase biochemical control (biochemical no evidence of disease - bNED) by 15-20% without increasing late rectal sequelae.
  • Early sequelae are predicted to decrease, provided overall treatment times are not drastically shortened (advising ≥5 weeks).
  • Even if prostate tumor alpha/beta is similar to or higher than rectal tissue, hypofractionated regimens are unlikely to significantly increase late effects.

Conclusions:

  • Suggested hypofractionated regimens for prostate cancer radiotherapy offer high potential therapeutic gain.
  • These protocols present economic and logistic advantages with minimal risk, provided excessively short overall times (<5 weeks) and very small fraction numbers (<5) are avoided.
  • The presented estimates for bNED and rectal complications are theoretical, derived from LQ modeling of existing clinical data for intermediate-risk prostate cancer.